Annexon Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
42.5%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Phase 3 ARCHER II Topline Data Readout (Vonaprument in GA) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly225MTarget: Sufficient to fund operations and planned milestones into the second half of 2027
Research and Development (R&D) Expenses Quarterly35.8MTarget: Optimized spending aligned with late-stage clinical trial progression
General and Administrative (G&A) Expenses Quarterly10.3MTarget: Controlled corporate overhead supporting regulatory filings
Watch Items
- Phase 3 ARCHER II Topline Data for Vonaprument (ANX007) in Geographic Atrophy (GA)Trigger: Topline data readout expected in Q4 2026Action: Evaluate clinical efficacy (vision preservation endpoints) and prepare for potential BLA submission in 2026
- U.S. BLA Submission for Tanruprubart (ANX005) in Guillain-Barré Syndrome (GBS)Trigger: Submission planned for 2026 supported by FORWARD study dataAction: Monitor FDA dialogue, complete enrollment in the FORWARD study, and prepare commercial infrastructure
- EMA Marketing Authorization Application (MAA) Review for Tanruprubart in GBSTrigger: MAA filed in January 2026 and currently under reviewAction: Respond to EMA day-120 and day-180 questions, and prepare for potential European launch
- ANX1502 Proof-of-Concept (POC) Trial in Cold Agglutinin Disease (CAD)Trigger: Data readout anticipated in 2026Action: Analyze pharmacokinetic, pharmacodynamic, and safety profiles to determine next-phase development
Research as of 19 Jun 2026